Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,601
datasets available to search
ShareScore release 0.9.0
Dataset results
1,601 results for “Prognosis;”
Potential biomarkers tah could help to determine the prognosis of azoospermia treatment
GEO Series GSE51111. Homo sapiens. 12 samples. Type: Expression profiling by array.
Pancreatic cancer prognosis is predicted by chromatin accessibility
GEO Series GSE124232. Homo sapiens. 225 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
SSEA-4 labels a subset of poor prognosis-associated osteosarcoma-initiating cells that respond to differentiation induction
GEO Series GSE58209. Homo sapiens. 6 samples. Type: Expression profiling by array.
Dissecting the AKT/mTOR pathway in estrogen receptor positive breast cancers identifies phosphorylated AKT to be associated with luminal A, PIK3CA mutations and good prognosis in contrast to phosphory
GEO Series GSE123834. Homo sapiens. 0 samples. Type: Expression profiling by array; Third-party reanalysis.
Anoctamin 5 regulates the cell cycle and affects prognosis in gastric cancer
GEO Series GSE189601. Homo sapiens. 2 samples. Type: Expression profiling by array.
EZH2 over-expression is associated with gain of chromosome arm 7q and essential for cell cycle progression and a marker of poor prognosis in neuroblastoma
GEO Series GSE28409. Homo sapiens. 9 samples. Type: Expression profiling by array.
Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis
GEO Series GSE308996. Homo sapiens. 23 samples. Type: Expression profiling by high throughput sequencing.
MicroRNA expression contributes to the poor prognosis of human small cell lung cancer
GEO Series GSE27435. Rattus norvegicus; Homo sapiens; Mus musculus. 42 samples. Type: Non-coding RNA profiling by array.
A five-gene signature is associated with tumor progression and poor prognosis in colorectal cancer
GEO Series GSE16934. Homo sapiens. 9 samples. Type: Expression profiling by array.
Blockade of TNFα after ischemia reperfusion injury ameliorates renal prognosis
GEO Series GSE39766. Mus musculus. 6 samples. Type: Expression profiling by array.
Dataset related to the article: Heart Failure Prognosis Over Time: How the Prognostic Role of Oxygen Consumption and Ventilatory Efficiency During Exercise Has Changed in the Last 20 Years
<p>This record contains raw data related to the article: Heart Failure Prognosis Over Time: How the Prognostic Role of Oxygen Consumption and Ventilatory Efficiency During Exercise Has Changed in the Last 20 Years, </p> <p>Eur J Heart Fail, 21 (2), 208-217 Feb 2019</p>
Dataset related to article "Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis? "
<p>This record contains raw data related to article "Pathologic tumor response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?"</p><p><strong>Abstract</strong></p><p>Neoadjuvant therapy (NAT) + surgical resection for pancreatic cancer (PC) has gained consensus in recent years. Pathological response (PR) is generally assessed according to the College of American Pathologists grading system, ranging from 0 (complete response) to 3 (no response). The aim of our study is to evaluate the PR in a series of resections for PC after NAT and its prognostic implication. 112 patients undergone NAT and resection for PC between 2011 and 2020 were retrospectively evaluated. PR was 0/1, 2 and 3 in 18 (15%), 79 (61%) and 29 (24%) cases, respectively. Chemotherapy regimens different from FOLFIRINOX and gemcitabine + nab-paclitaxel (OR 11.61 (2.53-53.36), p = 0.002) and lymphovascular invasion (OR 11.28 (1.89-67.23), p = 0.008) were associated to PR-3. Median follow-up was 25.8 (3.6-130.5) months. For PR-0/1, PR-2 and PR-3, median DFS was 45.8, 11.5, 4.6 months (p < 0.0001), respectively, while median OS was not reached, 27.1 and 17.5 months (p = 0.0006), respectively. At univariate analysis, PR-0/1 was significantly associated to better DFS and OS (HR 0.33 (0.17-0.67), p = 0.002; HR 0.20 (0.07-0.54), p = 0.002, respectively). At multivariate analysis, pancreaticoduodenectomy (HR 0.50 (0.30-0.84), p = 0.009), LNR (HR 27.14 (1.21-608.9), p = 0.038) and lymphovascular invasion (HR 1.99 (1.06-3.76), p = 0.033) were independently associated to DFS; pre-treatment CA 19.9 value (HR 1.00 (1.00-1.00), p = 0.025), post-treatment resectability status (HR 0.51 (0.28-0.95), p = 0.035), pancreaticoduodenectomy (HR 0.56 (0.32-0.99), p = 0.050), severe morbidity (2.99 (1.22-7.55), p = 0.017), LNR (HR 56.8 (2.08-1548.3), p = 0.017), lymphovascular invasion (HR 2.18 (1.08-4.37), p = 0.029) were independently associated to OS. PR did not reach statistical significance at multivariate analysis. A favorable PR is observed only in a limited number of cases. The prognostic role of PR, despite being promising, remains unclear and further multicentric studies are needed.</p>
Dataset related to article "Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients"
<p>This record contains raw data related to article "Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients"</p><p>Abstract</p><p><strong>Introduction: </strong>Residual tumor cellularity (RTC) and pathologic complete response (pCR) after neo-adjuvant chemotherapy (NAC) are prognostic factors associated with improved outcomes in breast cancer (BC). However, the majority of patients achieve partial pathologic response (pPR) and no clear correlation between RTC patterns and outcomes was described. Our aims were to define predictive factors for pCR and compare different outcomes of patients with pCR or pPR and with different RTC patterns.</p><p><strong>Materials and methods: </strong>Baseline and post-NAC demographics, clinicopathological characteristics, post-operative data, survival and recurrence status were recorded from our institutional database. A multivariable analysis was performed using a logistic regression model to identify independent predictors of pCR. Disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) analyses were performed using the Kaplan-Meier method.</p><p><strong>Results: </strong>Overall, of the 495 patients analyzed, 148 (29.9%) achieved pCR, 347 (70.1%) had pPR, and the median RTC was 40%. Multivariable analysis identified 3 independent factors predictive of pCR: tumor stage before NAC (cT1-2 84.5% versus cT3-4 15.5%), BC sub-type (HER2-positive 54.7% versus triple-negative 29.8% versus luminal-like 15.5%), and vascular invasion (absence 98.0% versus presence 2.0%). We found statistically significant longer DFS, DDFS, and OS in patients with pCR and with RTC <40%; no difference was observed in terms of OS between RTC <40% and RTC ≥40% groups.</p><p><strong>Conclusions: </strong>Tumor stage before NAC, BC sub-type, and vascular invasion are significant and independent factors associated with pCR. Patients with pCR and with RTC <40% have longer DFS, DDFS, and OS compared with patients with pPR.</p>
Dataset related to article "Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis"
<p>This record contains raw data related to article "Comparison of Long-Term Oncological Results in Young Women with Breast Cancer between BRCA-Mutation Carriers Versus Non-Carriers: How Tumor and Genetic Risk Factors Influence the Clinical Prognosis"</p><p><strong>Abstract</strong></p><p><strong>Background: </strong>Breast cancer (BC) is very uncommon in young women (YW) and it is unclear whether a BRCA mutation has prognostic implications. Our aim was to evaluate the characteristics of YW with BC by comparing the long-term oncological results between BRCA-mutation carriers and non-carriers.</p><p><strong>Methods: </strong>We retrospectively reviewed all the consecutive YW (aged 18-40 years) diagnosed with BC. Endpoints were disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS).</p><p><strong>Results: </strong>63 YW with a BRCA mutation were compared with 339 YW without BRCA mutation. BRCA-mutation carriers were younger (60.3% versus 34.8% if age ≤ 35 years, <i>p</i> = 0.001) and presented with more aggressive tumors (66.7% versus 40.7% if G3, <i>p</i> = 0.001; 57.2% versus 12.4% if biological subtype triple-negative, <i>p</i> = 0.001; 73.0% versus 39.2% if Ki67 ≥ 25%, <i>p</i> = 0.001). Non-carriers presented significantly better DFS, DDFS, and OS compared with BRCA-mutation carriers. Neoadjuvant chemotherapy was found to be an independent protective factor for OS in BRCA-mutation carriers.</p><p><strong>Conclusions: </strong>BC is more likely to present at a younger age (≤ 35 years) and with more aggressive characteristics (G3, triple-negative, Ki67 ≥ 25%) in YW with BRCA mutation compared with their non-mutated counterparts. Young BRCA-mutation carriers showed a poorer prognosis in terms of recurrence and survival compared with non-carriers. The implementation of neoadjuvant chemotherapy may improve survival in YW with BC and BRCA mutation.</p>
Dataset related to article "Definition of a multi-omics signature for Esophageal Adenocarcinoma prognosis prediction "
<p>This record contains raw data related to article “Definition of a multi-omics signature for Esophageal Adenocarcinoma prognosis prediction "</p> <p>Abstract: Esophageal cancer is a highly lethal malignancy that accounts for 5% of all cancer deaths. The two main sub-types of the disease are esophageal squamous-cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC). To date, most studies focused on analysing the transcriptional profile in ESCC only a few studies analysed EAC for transcriptional signatures that might be associated with diagnosis and/or prognosis. In this work we performed a single-cell RNA sequencing (scRNAseq) analysis of the CD45+ cells enriched from from tumor and matched non-tumor tissues obtained from 3 therapy-naïve patients to identify all the types of immune cells present in the tumor's immune infiltrate and their transcriptomic profiles, moreover we have analysed the whole transcriptome in a cohort of 23 patients from whom tissue biopsies were taken from tumor and matched non-tumor tissues. The transcriptional signatures derived from both types of analyses were then used to stratify a larger cohort of TCGA EAC patients showing a strong association with their prognosis. The transcriptional signatures here described have therefore proved capable of being able to predict the clinical outcome of patients and could be used to better define the prognosis in EAC after surgery and to direct patients towards effective therapies.</p>
Data set related to the article "Predictors of Prognosis in Patients With Secondary Mitral Regurgitation Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair"
<p>This record contains raw data related to the article <em>Predictors of Prognosis in Patients With Secondary Mitral Regurgitation Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair</em></p>
Differentially expressed genes in HBV related hepatic disease patients and the correlation with prognosis
GEO Series GSE267808. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Unraveling a mechanism driving poor-prognosis prostate cancer: overexpression of the DNA repair gene, ribonucleotide reductase small subunit M2
GEO Series GSE118845. Homo sapiens. 8 samples. Type: Genome binding/occupancy profiling by high throughput sequencing.
Dynamic Transcriptome Analysis Reveal New Prognosis Biomarker in Colorectal Cancer
GEO Series GSE41015. Homo sapiens; Mus musculus; Human alphaherpesvirus 1; Human betaherpesvirus 5; Human immunodeficiency virus 1; human gammaherpesvirus 4; JC polyomavirus; Human gammaherpesvirus 8; Betapolyomavirus macacae; Betapolyomavirus hominis; Rattus norvegicus. 66 samples. Type: Expression profiling by array; Non-coding RNA profiling by array.
DNA Methylation Data-based Molecular Subtype Classification Related to the Prognosis in Patients with esophageal carcinoma
<p>Supplemental Materials of the manuscript named "DNA Methylation Data-based Molecular Subtype Classification Related to the Prognosis in Patients with esophageal carcinoma",which have been submitted to the journal <em>international journal of molecular sciences</em></p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.